During the quarter, total expenses rose 35.88% to Rs 1,479.85 crore. Cost of material consumed climbed 33.36% to Rs 928.43 crore while employee expense rose 19.51% to Rs 251.49.

The board has recommended a dividend of Rs 30 per share for the financial year 2021-22.

On a consolidated basis, Divi's Laboratories earned a total revenue of Rs 9074 crore for the financial year 2021-22 as against Rs 7032 crore during the previous year, reflecting a growth of 29%. PBT for the current year grew by 38% to Rs 3684 crore as against a PBT of Rs 2666 crore for the previous year. PAT for the year amounted to Rs 2960 crore as against a PAT of Rs 1984 crore for the last year, reflecting a growth of 49%.

Net cash flow from operating activities soared to Rs 1911.80 crore as on 31 March 2022 lower than Rs 1946.93 crore as on 31 March 2021.

During the year 2021-22, the company has capitalized assets valuing Rs 934.56 crore. Capital Work in Progress (CWIP) as at the year-end amounted to Rs 469.93 crore.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.